EKG

Best Life Insurance Plans for Diabetics - Our Top Picks for 2024

Retrieved on: 
星期一, 二月 12, 2024
A1C, Database, Lincoln National Corporation, Legal & General, History, ICC, Diagnosis, Diabetes, American Diabetes Association, Insulin, Pancreas, Mutual, CDC, Immune system, Anxiety, Woman, AEGON, Corebridge Financial, Prediabetes, Life expectancy, Insulin resistance, John Hancock Financial, Research, Insurance, SBLI, Roger Hawkins (drummer), MD, Prudential Financial, Cell, EKG, Policy, Privacy, Pharmaceutical industry

Continued Bland, "Our 50-insurer database is continually updated, which makes it a valuable resource for diabetics who are searching for the best buys in life insurance."

Key Points: 
  • Continued Bland, "Our 50-insurer database is continually updated, which makes it a valuable resource for diabetics who are searching for the best buys in life insurance."
  • Instant life insurance quotes for both type 1 and type 2 diabetics are available at www.lifequotes.com .
  • Life insurance policies described, quoted, shown and illustrated throughout this press release may not be available in all states.
  • Pacific Life Insurance Company of Newport Beach, CA, policy form P16LYT or ICC 16 P16LYT.

RAJANT INTRODUCES DISTRIBUTED EDGE AI PLATFORM AT CES

Retrieved on: 
星期一, 一月 8, 2024
LoRa, Ecosystem, Consumer Electronics Show, BLE, Software, Marketing, RHI, Health, Cowbell, Artificial intelligence, VPN, Skin temperature, AI, Internet of things, GPU, Animal, CPU, Kinetic, Lighting control system, Doctor of Philosophy, EKG, Bluetooth, Safety, CES, API, Video game

Known as the Cowbell, the edge AI platform is a distributed computing hub and platform-as-a-service to streamline and simplify the delivery and management of AI applications at the edge.

Key Points: 
  • Known as the Cowbell, the edge AI platform is a distributed computing hub and platform-as-a-service to streamline and simplify the delivery and management of AI applications at the edge.
  • The Cowbell platform simplifies this complex problem by providing software, hardware, and networking infrastructure necessary to bring distributed cloud native computing to the edge with what we’re calling MLOps-in-a-Box.
  • By leveraging Rajant’s patented InstaMesh® networking technology, the Cowbell platform facilitates a secure, fault-tolerant, highly available distributed computing cluster over mesh, the first of its kind.
  • Schedule a time to meet at CES or stop by Zeno 4610 within The Venetian to see the latest Rajant family of products.

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Retrieved on: 
星期四, 一月 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Psychiatry, XETRA, ADOS, Medication, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • Ravi Anand, Newron’s Chief Medical Officer, said: “Treatment with evenamide as an add-on to antipsychotics in TRS patients has produced benefits that have never been reported before.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

Retrieved on: 
星期四, 一月 4, 2024
Psychiatry, XETRA, ADOS, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • 25% of all patients achieved “remission” (see “About remission”), never described before in TRS patients.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

Retrieved on: 
星期三, 一月 3, 2024
IVUS, Partnership, Risk, CCTA, Physician, FDA, Plaque, CAD, PET, Health, Negative, ACC, Hospital, SCCT, Medicare, Artificial intelligence, EKG, Foreign policy, Growth, Patient, Diagnosis, SPECT

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis.
  • HeartFlow’s FFRCT provides clear insights into each patient’s condition with a patient-specific visual model of the heart’s blood flow.
  • Since its inception, HeartFlow has been committed to building a new standard of care for people at risk of heart disease.
  • “We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMapTM Analysis.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

Retrieved on: 
星期三, 十二月 20, 2023
Quality of life, MRI, Hippocampus, Hypoplastic left heart syndrome, Diffusion MRI, Neuron, Disease, Brain, Incidence, Hypersensitivity, Magnetic resonance imaging, CLEAR, Week, Mini–Mental State Examination, Dementia, Degree, Atrophy, TBV, EKG, DTI, Patient, Thalamus, Magnetic resonance, Safety, Siderosis, HLHS, Alzheimer's disease, Medical imaging

The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.

Key Points: 
  • The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.
  • Wa’el Hashad, CEO of Longeveron, commented: “These new data support our initial results for CLEAR MIND that we announced in October and provide further validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of mild Alzheimer’s disease.
  • In addition to these clinical findings, brain imaging showed improvement in brain architecture measured by volumetric MRI and DTI, respectively.
  • Taken together, the Company believes the results of the CLEAR MIND study build a strong foundation for further development in mild Alzheimer's disease patients.

Safe & Sound Holiday Tips for Seniors According to Lisa M. Cini

Retrieved on: 
星期一, 十一月 27, 2023
Mental Health, Wearables, Mobile Technology, Technology, Seniors, Home Goods, Managed Care, Consumer, Health, Retail, Consumer Electronics, Holiday, Blood pressure, EKG, Transport, Social isolation, Smartphone, Sadness, Heart, Friends, Table tennis rubber, Relaxation, Lilly, Ageing, Loop, Christmas, FaceTime, CDC, Heat, Cooking, Family, Alertness, Quality of life, Fire, Injury, Somnolence, Tourism, Tile

Aging expert Lisa M. Cini emphasizes the importance of prioritizing accessibility, functionality, and efficiency for aging loved ones.

Key Points: 
  • Aging expert Lisa M. Cini emphasizes the importance of prioritizing accessibility, functionality, and efficiency for aging loved ones.
  • “The holiday season should be filled with joy, not feelings of sadness or trips to the ER,” says leading aging expert Lisa M. Cini .
  • Safe Holiday Travels: Ensure a smooth journey for aging loved ones by planning ahead.
  • Address potential hazards, secure safe and accessible accommodations, arrange comfortable transportation, and prioritize the senior's health throughout the trip.

Probo Medical Completes Acquisition of Davis Medical

Retrieved on: 
星期四, 十一月 16, 2023
Growth, EKG, Avista Capital Partners, Acquisition, UC Davis Medical Center, Cardiology, Pharmaceutical industry, Probo, Vista

TAMPA, Fla., Nov. 16, 2023 /PRNewswire/ -- Probo Medical ("Probo"), a leading global provider of medical imaging equipment, parts, repair and service, announced the acquisition of Davis Medical Electronics, Inc. ("Davis Medical").

Key Points: 
  • TAMPA, Fla., Nov. 16, 2023 /PRNewswire/ -- Probo Medical ("Probo"), a leading global provider of medical imaging equipment, parts, repair and service, announced the acquisition of Davis Medical Electronics, Inc. ("Davis Medical").
  • Davis Medical, founded in 1983 in Vista, CA, led Randy Davis and Marion Davis, is a leading provider of equipment and supplies for cardiology practices.
  • "Our team at Davis Medical has known the Probo team for decades.
  • Probo's capabilities in the areas of equipment sales, repairs and servicing will bring added depth to the value that the Davis Medical team can offer to our customers," said Randy Davis, Founder and CEO of Davis Medical.

Walmart Health Expands Access to Affordable Care in Florida With Ambetter from Sunshine Health and Orlando Health Collaborations

Retrieved on: 
星期三, 十一月 1, 2023
Retail, Health Insurance, Telemedicine, Virtual Medicine, Technology, Pharmaceutical, Managed Care, General Health, Online Retail, Hospitals, Other Retail, Department Stores, Nursing, Internet, Health, Mobile, Wireless, Centene Corporation, Insurance, Practitioner, Big-box store, NYSE, Innovation, Walmart, Massachusetts Institute of Technology, Ambetter Health 400, Physician, CNC, Sunshine & Health, Senior, Community, EKG, Orlando Health, Patient, Communication, Sunlight, Medicaid

Ambetter from Sunshine Health now includes Walmart Health Centers as a preferred provider in Clay, Duval, Hillsborough, Orange, Osceola, Pasco and Seminole counties in Florida through the Ambetter Value Plan.

Key Points: 
  • Ambetter from Sunshine Health now includes Walmart Health Centers as a preferred provider in Clay, Duval, Hillsborough, Orange, Osceola, Pasco and Seminole counties in Florida through the Ambetter Value Plan.
  • “Both Walmart Health and Ambetter Health share a focus on serving local communities, and this collaboration will enable more Floridians to access care.
  • Ultimately, this will broaden access to care for more Floridians through Ambetter from Sunshine Health,” said CEO of Ambetter Health, Kevin Counihan.
  • Walmart Health and Orlando Health are working together to serve the Orlando community through care coordination activities designed to make it easier for Orlando area residents and their providers to coordinate a patient’s health care journey.

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s

Retrieved on: 
星期二, 十月 24, 2023
Magnetic resonance, IBN, MRI, Alzheimer's disease, Ageing, Incidence, Shimaa Hashad, HLHS, Magnetic resonance imaging, ARIA, MD, News, Data, SAE, EKG, Safety, Hypersensitivity, DSMB, Pharmaceutical industry, Medical imaging

The audio news release covers Longeveron’s recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

Key Points: 
  • The audio news release covers Longeveron’s recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.
  • There was one Serious Adverse Event (SAE) reported on each Lomecel-B™ treatment group and none on placebo.
  • “These study results with Lomecel-B™ are encouraging,” Dr. Jeffrey Cummings, MD, Vice Chair of Research, UNLV Department of Brain Health, added.
  • Despite progress for new anti-amyloid treatment, there remains a high unmet medical need.